In brief
Federal officials have approved a second generic version of the abortion pill mifepristone, sparking backlash from anti-abortion activists. The approval by Evita Solutions comes as the FDA faces scrutiny over the drug's 25-year history and continued accessibility, particularly due to state laws that limit its use.
WASHINGTON (AP) — The FDA has granted approval for another generic version of the abortion pill mifepristone, leading to immediate criticism from anti-abortion groups linked to the Trump administration. The drug manufacturer Evita Solutions announced the approval of its low-cost variant of the medication, approved for terminating pregnancies within 10 weeks.
Students for Life Action, an anti-abortion organization, condemned the approval as 'a stain on the Trump presidency' and emphasized that the FDA needs reform. This decision heightens tensions as Trump-appointed health officials, including Health Secretary Robert F. Kennedy Jr., face calls from anti-abortion advocates to investigate the safety of mifepristone, which has been regarded as safe and effective since its approval in 2000.
In correspondence to Republican attorneys general, Kennedy, along with FDA Commissioner Dr. Marty Makary, committed to reviewing the drug's safety profile.
The FDA's approval process for generic drugs typically follows a routine procedure; however, the approval for Evita's generic mifepristone comes after a four-year wait. The original approval of mifepristone in 2000 was followed by a relaxation of access, including the introduction of the first generic pill from GenBioPro in 2019.
In 2021, the FDA under President Joe Biden expanded access to mifepristone by allowing online prescribing and mail-order delivery, a move that has faced opposition from abortion opponents ever since.
Obtaining generic drug approvals typically doesn't draw significant attention, but this case adds fuel to the fire of the ongoing abortion access debate. The new generic version may not significantly change access to mifepristone, particularly in areas where state laws impose strict regulations or outright bans on abortion services.
Concerns regarding the legality surrounding mifepristone are echoed across numerous lawsuits navigating the judicial system, while prominent medical institutions like the American Medical Association oppose these restrictions.
Evita Solutions expressed its commitment to ensuring that every person has access to 'safe, affordable, high-quality, effective, and compassionate abortion care,' yet the implications of this approval will continue to echo amid an evolving political and legal landscape surrounding abortion rights.
